Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Response to Cobitz and Ambery
- David M. Nathan, MD1,2 and
- for the American Diabetes Association and European Association for the Study of Diabetes Consensus Committee
- 1Massachusetts General Hospital Diabetes Center, Boston, Massachusetts;
- 2Harvard Medical School, Boston, Massachusetts.
- Corresponding author: David M. Nathan, dnathan{at}partners.org
We are not surprised that GlaxoSmithKline, the manufacturer of rosiglitazone (Avandia), is not happy with the recommendation of the consensus group (1) that rosiglitazone not be used in the treatment of type 2 diabetes (2). Drs. Cobitz and Ambery argue that the consensus group used data selectively, did not consistently apply criteria for selecting interventions, and unfairly dismissed the use of rosiglitazone. They note the absence of conclusive data regarding the safety of rosiglitazone, citing meta-analyses, including one by the U.S. Food and Drug Administration (FDA), that, according to Cobitz and Ambery, reported “no increase in cardiovascular ischemic risk with rosiglitazone,” and state …
